Dynamics of the gut-liver axis in rats with varying fibrosis severity

被引:14
|
作者
Xiang, Hongyan [1 ]
Liu, Zongyi [1 ]
Xiang, Huanyu [1 ]
Xiang, Dejuan [1 ]
Xiao, Shuang [1 ]
Xiao, Jing [1 ]
Shen, Wei [1 ]
Hu, Peng [1 ]
Ren, Hong [1 ]
Peng, Mingli [1 ]
机构
[1] Chongqing Med Univ, Key Lab Mol Biol Infect Dis, Affiliated Hosp 2, Inst Viral Hepatitis,Dept Infect Dis,Minsit Educ, Chongqing 400010, Peoples R China
来源
关键词
gut-liver axis; liver fibrosis; gut microbiota; bile acid; gut barrier; BILE-SALT HYDROLASE; MICROBIOTA; BARRIER; LACTOBACILLUS; CROSSTALK; CIRRHOSIS; DYSBIOSIS; ACIDS; MODEL;
D O I
10.7150/ijbs.69833
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The classic carbon tetrachloride (CCl4)-induced liver injury model is widely used to study the pathogenesis of fibrosis and evaluate anti-fibrosis drugs. Here, we investigated the dynamic changes in the gut microbiota, bile acids (BAs) and the gut barrier over different fibrosis severities in a CCl4-based model. 16S rDNA sequencing demonstrated that the beneficial taxon Lactobacillus was always underrepresented, and pathogens including Escherichia_Shigella, Clostadium_sensu_stacto_1, Colidextribacter, and Lachnospiraceae_UCG_010 were significantly overrepresented across liver fibrosis severities. Gut dysbiosis was more severe at the early stage of liver injury and advanced stage of fibrosis. An ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) analysis revealed that with the progress of fibrosis, unconjugated BAs in faeces were significantly decreased and conjugated BAs in serum were significantly increased. The FXR-SHP signalling pathway in the liver and ileum was statistically repressed in the fibrosis groups. Determination of lipopolysaccharide (LPS) and fluorescein isothiocyanate (FITC)-dextran levels in plasma showed that the intestinal barrier remained relatively intact in the advanced fibrosis stage. The advances in knowledge of the gut-liver axis provided by this study yield new insights for application in research and drug evaluation.
引用
收藏
页码:3390 / 3404
页数:15
相关论文
共 50 条
  • [21] The gut-liver axis in hepatobiliary diseases
    Masataka Ichikawa
    Haruka Okada
    Nobuhiro Nakamoto
    Nobuhito Taniki
    Po-Sung Chu
    Takanori Kanai
    Inflammation and Regeneration, 44
  • [22] The gut-liver axis in hepatobiliary diseases
    Ichikawa, Masataka
    Okada, Haruka
    Nakamoto, Nobuhiro
    Taniki, Nobuhito
    Chu, Po-Sung
    Kanai, Takanori
    INFLAMMATION AND REGENERATION, 2024, 44 (01)
  • [24] The gut-liver axis as a target of liver disease management
    Mandato, Claudia
    Bovi, Anna Pia Delli
    Vajro, Pietro
    HEPATOBILIARY SURGERY AND NUTRITION, 2021, 10 (01) : 100 - 102
  • [25] Viral Liver Disease and Intestinal Gut-Liver Axis
    Kouroumalis, Elias
    Tsomidis, Ioannis
    Voumvouraki, Argyro
    GASTROINTESTINAL DISORDERS, 2024, 6 (01): : 64 - 93
  • [26] The Gut-Liver Axis in Pediatric Liver Health and Disease
    Rager, Stephanie L.
    Zeng, Melody Y.
    MICROORGANISMS, 2023, 11 (03)
  • [27] Importance of the gut microbiota in the gut-liver axis in normal and liver disease
    Kotlyarov, Stanislav
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (06)
  • [28] Gut-liver axis: barriers and functional circuits
    Pabst, Oliver
    Hornef, Mathias W.
    Schaap, Frank G.
    Cerovic, Vuk
    Clavel, Thomas
    Bruns, Tony
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2023, 20 (07) : 447 - 461
  • [29] The Gut-Liver Axis in Primary Sclerosing Cholangitis
    Eksteen, Bertus
    CLINICS IN LIVER DISEASE, 2016, 20 (01) : 1 - +
  • [30] Gut-liver axis in health and disease Abstracts
    不详
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2015, 1 (02) : 51 - 96